Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP4 | P49662 | 1/20 | 0.44 |
| ▸ | CASP5 | P51878 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16652554 | 0.98 | KDM4E (0.62) | KDM4EALDH1A1TAAR1CHRNB2CHRNA4 | |
| SCHEMBL3188491 | 0.93 | CHRNB2 (0.55) | KDM4EALDH1A1TAAR1CHRNB2CHRNA4 | |
| SCHEMBL1433020 | 0.80 | ALDH1A1 (0.47) | KDM4EALDH1A1HRH1SMN1; SMN2TSHR | |
| SCHEMBL3323407 | 0.80 | KDM4E (0.43) | KDM4EALDH1A1CHRNB2CHRNA4USP2 | |
| SCHEMBL25255051 | 0.79 | ALDH1A1 (0.59) | KDM4EALDH1A1TAAR1CHRNB2CHRNA4 | |
| SCHEMBL7991455 | 0.79 | ALDH1A1 (0.59) | KDM4EALDH1A1TAAR1CHRNB2CHRNA4 | |
| SCHEMBL2274356 | 0.79 | ALDH1A1 (0.59) | KDM4EALDH1A1TAAR1CHRNB2CHRNA4 | |
| SCHEMBL5102919 | 0.79 | ALDH1A1 (0.59) | KDM4EALDH1A1TAAR1CHRNB2CHRNA4 | |
| SCHEMBL4476809 | 0.79 | KDM4E (0.59) | KDM4EALDH1A1TAAR1CHRNB2CHRNA4 | |
| SCHEMBL3668289 | 0.79 | ALDH1A1 (0.59) | KDM4EALDH1A1TAAR1CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303497-A1 | DEUTERATED 5-HT1A RECEPTOR AGONISTS | CONRIG PHARMA APS (DK) | 2013-11-14 | — | — | US | claimed |
| EP-2601187-A1 | DEUTERATED TANDOSPIRONE DERIVATIVES AS 5-HT1A RECEPTOR AGONISTS | Conrig Pharma ApS (DK) | 2013-06-12 | — | — | EP | claimed |
| WO-2012016569-A1 | DEUTERATED TANDOSPIRONE DERIVATIVES AS 5-HT1A RECEPTOR AGONISTS | CONRIG PHARMA APS (DK) | 2012-02-09 | — | — | WO | claimed |
| EP-4551570-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Dong-A ST Co., Ltd. (KR) | 2025-05-14 | — | — | EP | disclosed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| CN-119403798-A | Novel compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | 东亚ST 株式会社 | 2025-02-07 | — | — | CN | disclosed |
| WO-2024222726-A1 | DEGRADATION AGENT FOR CYCLIN-DEPENDENT KINASE (CDK) 12/13, COMPOSITION AND USE THEREOF | 浙江大学 | 2024-10-31 | — | — | WO | disclosed |
| CN-118440054-A | Degradation agent, composition and application of cyclin-dependent kinase 12/13 | 浙江大学 | 2024-08-06 | — | — | CN | disclosed |
| US-20240246961-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-07-25 | — | — | US | disclosed |
| US-11970493-B2 | Autotaxin inhibitor compounds | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-04-30 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| WO-2003014092-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | ASTRAZENECA AB (SE) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002046151-A1 | DELTA 1-PYRROLINES USED AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| US-20020037900-A1 | Hydroxamic acid derivatives | DARWIN DISCOVERY LIMITED (GB) | 2002-03-28 | — | — | US | disclosed |
| US-4994460-A | Treatment or prevention of disorders resulting from central nervous system anoxia | BRISTOL-MYERS SQUIBB CO. (US) | 1991-02-19 | — | — | US | disclosed |
| EP-0400661-A1 | Agents for treatment of brain ischemia | Bristol-Myers Squibb Company (US) | 1990-12-05 | — | — | EP | disclosed |
| EP-0200968-B1 | SUCCINIMIDE DERIVATIVES, THEIR PRODUCTION AND USE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-08-29 | — | — | EP | disclosed |
| US-4843078-A | ANXIOLYTIC AGENTS | SUMITONO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-06-27 | — | — | US | disclosed |
| EP-0200968-A1 | Succinimide derivatives, their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-11-12 | — | — | EP | disclosed |
| US-4605655-A | NEUROLEPTIC AGENTS; NO MOVEMENT DISORDER SIDE EFFECTS | BRISTOL-MYERS COMPANY (US) | 1986-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303497-A1 | DEUTERATED 5-HT1A RECEPTOR AGONISTS | HTR1A, HTR1D, HTR5A | KDM4E 3259/4885ALDH1A1 620/4885TAAR1 44/4885 |
| US-20240246961-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, ATXN10, ATXN2L | KDM4E 1416/4885ALDH1A1 4721/4885TAAR1 3421/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | KDM4E 4591/4885ALDH1A1 3927/4885TAAR1 4543/4885 |
| US-20020037900-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | KDM4E 2214/4885ALDH1A1 644/4885TAAR1 3804/4885 |
| US-11970493-B2 | Autotaxin inhibitor compounds | ENPP2, ATXN10, ATXN2L | KDM4E 1416/4885ALDH1A1 4721/4885TAAR1 3421/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | KDM4E 4591/4885ALDH1A1 3927/4885TAAR1 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.